Navion Neurosciences
Navion Neurosciences is a preclinical-stage biotech. Its NaViGATion platform combines AI-enabled chemistry, structural biology, human disease biology and ion-channel expertise. The platform is used to discover sodium-channel therapeutics for neuronal hyperexcitability, aimed at patients with genetic epilepsy and chronic neuropathic pain. It is a venture-backed drug developer and has no commercial product. In 2026 it announced a $10.8M first closing of a seed round led by the Angelini Lumira Biosciences Fund. Other participants were 3B Future Health Fund, UVA LVG Seed Fund, Virginia Innovation Partnership Corporation, VTC Innovation Fund and management. The company's technology is based on intellectual property licensed from University of Virginia researcher Manoj Patel, and Andrew Krouse is founder and CEO.